89bio, Inc. (NASDAQ: ETNB ) continues advancing with Pegozafermin, a long-acting FGF21 analog, through Phase 3 trials. Pegozafermin is particularly promising as it targets large TAMs with unmet needs in MASH with and without cirrhosis, and severe hypertriglyceridemia (SHTG). The company is pursuing a dual-path approval strategy. First, anMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. de ...